{"entity":{"type":"insider","cik":"0001706176","url":"/insider/0001706176","json_url":"/insider/0001706176.json","name":"Chevallard Daniel R.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":17,"first":"2017-07-25","last":"2026-03-30","span_basis":"filed_date"},"name_variants":[{"name":"Chevallard Daniel R.","source":"filing","n_filings":17,"first_seen":"2017-07-25","last_seen":"2026-03-30"}],"transactions":[{"id":5828455,"accession":"0001706176-26-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001706176-26-000004","line_url":"/filing/0001706176-26-000004#line-1","is_derivative":false,"issuer_cik":"0001706176","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001706176","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.57,"price_display":"8.57","price_state":"stated","total_value":64275.0,"total_display":"64,275.00","shares_owned_after":12886.0,"shares_owned_after_display":"12,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-27","filed_date":"2026-03-30","scope":"insider"},{"id":4517294,"accession":"0001815776-25-000072","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001815776-25-000072","line_url":"/filing/0001815776-25-000072#line-2","is_derivative":false,"issuer_cik":"0001706176","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001706176","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2178.0,"shares_display":"2,178","price_per_share":22.7561,"price_display":"22.76","price_state":"stated","total_value":49562.7858,"total_display":"49,562.79","shares_owned_after":5386.0,"shares_owned_after_display":"5,386","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-07","filed_date":"2025-11-07","scope":"insider"},{"id":4517291,"accession":"0001815776-25-000072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001815776-25-000072","line_url":"/filing/0001815776-25-000072#line-1","is_derivative":false,"issuer_cik":"0001706176","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001706176","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20.0,"shares_display":"20","price_per_share":22.71,"price_display":"22.71","price_state":"stated","total_value":454.2,"total_display":"454.20","shares_owned_after":3208.0,"shares_owned_after_display":"3,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-07","filed_date":"2025-11-07","scope":"insider"},{"id":2196642,"accession":"0001815776-24-000046","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001815776-24-000046","line_url":"/filing/0001815776-24-000046#line-1","is_derivative":false,"issuer_cik":"0001706176","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001706176","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3188.0,"shares_display":"3,188","price_per_share":15.68,"price_display":"15.68","price_state":"stated","total_value":49987.84,"total_display":"49,987.84","shares_owned_after":3188.0,"shares_owned_after_display":"3,188","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-14","filed_date":"2024-05-15","scope":"insider"},{"id":2640790,"accession":"0001209191-24-004037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-004037","line_url":"/filing/0001209191-24-004037#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3405.0,"shares_display":"3,405","price_per_share":0.7322,"price_display":"0.73","price_state":"stated","total_value":2493.141,"total_display":"2,493.14","shares_owned_after":102306.0,"shares_owned_after_display":"102,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-27","scope":"insider"},{"id":8441641,"accession":"0001209191-23-056842","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-056842","line_url":"/filing/0001209191-23-056842#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3720.0,"shares_display":"3,720","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":1860.0,"total_display":"1,860.00","shares_owned_after":98822.0,"shares_owned_after_display":"98,822","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-28","filed_date":"2023-11-28","scope":"insider"},{"id":8470445,"accession":"0001209191-23-047665","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-047665","line_url":"/filing/0001209191-23-047665#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3512.0,"shares_display":"3,512","price_per_share":1.45,"price_display":"1.45","price_state":"stated","total_value":5092.4,"total_display":"5,092.40","shares_owned_after":95653.0,"shares_owned_after_display":"95,653","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-28","filed_date":"2023-08-29","scope":"insider"},{"id":8438903,"accession":"0001209191-23-032707","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-032707","line_url":"/filing/0001209191-23-032707#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3635.0,"shares_display":"3,635","price_per_share":1.4196,"price_display":"1.42","price_state":"stated","total_value":5160.246,"total_display":"5,160.25","shares_owned_after":92277.0,"shares_owned_after_display":"92,277","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-26","scope":"insider"},{"id":8214834,"accession":"0001209191-23-013854","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-013854","line_url":"/filing/0001209191-23-013854#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3599.0,"shares_display":"3,599","price_per_share":1.6812,"price_display":"1.68","price_state":"stated","total_value":6050.6388,"total_display":"6,050.64","shares_owned_after":89023.0,"shares_owned_after_display":"89,023","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-02-28","scope":"insider"},{"id":6548954,"accession":"0001209191-22-058981","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-058981","line_url":"/filing/0001209191-22-058981#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3532.0,"shares_display":"3,532","price_per_share":2.7196,"price_display":"2.72","price_state":"stated","total_value":9605.6272,"total_display":"9,605.63","shares_owned_after":85733.0,"shares_owned_after_display":"85,733","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-28","filed_date":"2022-11-29","scope":"insider"},{"id":6277703,"accession":"0001209191-22-047948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-047948","line_url":"/filing/0001209191-22-047948#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3655.0,"shares_display":"3,655","price_per_share":4.0162,"price_display":"4.02","price_state":"stated","total_value":14679.211,"total_display":"14,679.21","shares_owned_after":82376.0,"shares_owned_after_display":"82,376","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-26","filed_date":"2022-08-29","scope":"insider"},{"id":6630621,"accession":"0001209191-22-032665","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-032665","line_url":"/filing/0001209191-22-032665#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3596.0,"shares_display":"3,596","price_per_share":1.9011,"price_display":"1.90","price_state":"stated","total_value":6836.3556,"total_display":"6,836.36","shares_owned_after":79142.0,"shares_owned_after_display":"79,142","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-26","filed_date":"2022-05-27","scope":"insider"},{"id":6542406,"accession":"0001209191-22-014438","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-014438","line_url":"/filing/0001209191-22-014438#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3998.0,"shares_display":"3,998","price_per_share":2.7795,"price_display":"2.78","price_state":"stated","total_value":11112.441,"total_display":"11,112.44","shares_owned_after":75849.0,"shares_owned_after_display":"75,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-01","scope":"insider"},{"id":5209435,"accession":"0001209191-21-067045","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-067045","line_url":"/filing/0001209191-21-067045#line-3","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4325.0,"shares_display":"4,325","price_per_share":4.8191,"price_display":"4.82","price_state":"stated","total_value":20842.6075,"total_display":"20,842.61","shares_owned_after":72958.0,"shares_owned_after_display":"72,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-29","filed_date":"2021-11-29","scope":"insider"},{"id":5209434,"accession":"0001209191-21-067045","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-067045","line_url":"/filing/0001209191-21-067045#line-2","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"Viracta Therapeutics, Inc.","issuer_ticker":"VIRX","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (CFO and COO)","officer_title":"CFO and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3254.0,"shares_display":"3,254","price_per_share":4.8006,"price_display":"4.80","price_state":"stated","total_value":15621.1524,"total_display":"15,621.15","shares_owned_after":77283.0,"shares_owned_after_display":"77,283","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-26","filed_date":"2021-11-29","scope":"insider"},{"id":8453750,"accession":"0001209191-19-040500","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-040500","line_url":"/filing/0001209191-19-040500#line-1","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2669.0,"shares_display":"2,669","price_per_share":1.3115,"price_display":"1.31","price_state":"stated","total_value":3500.3935,"total_display":"3,500.39","shares_owned_after":77870.0,"shares_owned_after_display":"77,870","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-01","filed_date":"2019-07-02","scope":"insider"},{"id":8646072,"accession":"0001209191-19-030506","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-030506","line_url":"/filing/0001209191-19-030506#line-2","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":1.4089,"price_display":"1.41","price_state":"stated","total_value":14089.0,"total_display":"14,089.00","shares_owned_after":80539.0,"shares_owned_after_display":"80,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-15","filed_date":"2019-05-16","scope":"insider"},{"id":8344674,"accession":"0001209191-19-023087","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-023087","line_url":"/filing/0001209191-19-023087#line-1","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3253.0,"shares_display":"3,253","price_per_share":0.9814,"price_display":"0.98","price_state":"stated","total_value":3192.4942,"total_display":"3,192.49","shares_owned_after":9372.0,"shares_owned_after_display":"9,372","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-01","filed_date":"2019-04-03","scope":"insider"},{"id":4743020,"accession":"0001209191-17-046232","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-046232","line_url":"/filing/0001209191-17-046232#line-1","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":"0001706176","owner_name":"Chevallard Daniel R.","owner_url":"/insider/0001706176","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":54945.0,"shares_display":"54,945","price_per_share":0.91,"price_display":"0.91","price_state":"stated","total_value":49999.95,"total_display":"49,999.95","shares_owned_after":59415.0,"shares_owned_after_display":"59,415","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-25","filed_date":"2017-07-25","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":5,"open_market":true},{"code":"S","label":"Open-market sale","n":14,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815776","name":"LENZ Therapeutics, Inc.","url":"/issuer/0001815776","role":"Officer (Chief Financial Officer)","n_filings":3,"first_seen":"2024-05-15","last_seen":"2026-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001061027","name":"Viracta Therapeutics, Inc.","url":"/issuer/0001061027","role":"Officer (CFO and COO)","n_filings":10,"first_seen":"2021-11-29","last_seen":"2024-02-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001505512","name":"Regulus Therapeutics Inc.","url":"/issuer/0001505512","role":"Officer (Chief Financial Officer)","n_filings":4,"first_seen":"2017-07-25","last_seen":"2019-07-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001706176","retrieved_at":"2026-08-21T07:59:53+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}